Geron Corp. : Geron Announces Presentations at the American Association for Cancer Research Annual Meeting MENLO PARK, Calif., April 9, 2013 - Geron Corporation (Nasdaq: GERN) today announced presentation of the final results from the Phase 2 study of imetelstat, the company's first-in-class telomerase inhibitor, as maintenance therapy following platinum-based induction chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) at the American Association for Cancer Research (AACR) 2013 Annual Meeting, currently taking place in Washington, D.C. In September 2012, top-line results for the overall study population reported only a minimal impact on progression-free survival (PFS) in NSCLC patients who received imetelstat. Using a retrospective measurement of tumor telomere length, a preliminary subgroup analysis of NSCLC patients suggested that patients whose tumors had short telomeres at baseline experienced an increase in PFS when treated with imetelstat in comparison to patients in the control arm. In a recently completed updated subgroup analysis using a refined prospective assay to measure tumor telomere length and more mature clinical data, the magnitude of the treatment effect in patients whose tumors had short telomeres was not reproduced. The final data from the Phase 2 study, including the results from the recent updated subgroup analysis, will be presented in two posters: Title: Improved Progression-Free Survival (PFS) in Patients with Short Tumor Telomere Length: Subgroup Analysis from a Randomized Phase 2 Study of the Telomerase Inhibitor Imetelstat as Maintenance Therapy for Advanced NSCLC Date & Time: Tuesday, April 9, 8:00 a.m. - 12:00 p.m. ET Abstract #: 2376 Location: Hall A-C, Poster Section 1 Title: A Randomized Phase 2 Study of the Telomerase Inhibitor Imetelstat as Maintenance Therapy for Advanced Non-Small Cell Lung Cancer Date & Time: Wednesday, April 10, 8:00 a.m. - 12:00 p.m. ET Abstract #: 4660 Location: Hall A-C, Poster Section 2 In accordance with AACR publication rules, the posters will be made available on the company's website at www.geron.com concurrently with the date and time of the conference presentations. About Imetelstat Imetelstat is a potent and specific inhibitor of telomerase. This first-in-class compound is a specially designed and modified short oligonucleotide, which targets and binds directly and with high affinity to the active site of telomerase. Unique and proprietary oligonucleotide chemistry improves binding affinity and stability in plasma and tissues. A lipid modification enables cellular and tissue penetration and biodistribution. To date, clinical data from Phase 2 studies indicate that imetelstat has activity against hematologic malignancies, specifically essential thrombocythemia, which provides clinical rationale for evaluating imetelstat as a potential treatment for other hematologic myeloid malignancies where there is a greater unmet need. Imetelstat is being currently evaluated in patients with myelofibrosis through an investigator-sponsored trial conducted at the Mayo Clinic. About Geron Geron is a biopharmaceutical company developing first-in-class therapies for cancer, including its telomerase inhibitor, imetelstat, in clinical development. For more information about Geron, visit www.geron.com. CONTACT: Anna Krassowska, Ph.D. Investor and Media Relations 650-473-7765 firstname.lastname@example.org email@example.com ### ------------------------------------------------------------------------------ This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Geron Corp. via Thomson Reuters ONE HUG#1691429
Geron Corp. : Geron Announces Presentations at the American Association for Cancer Research Annual Meeting
Press spacebar to pause and continue. Press esc to stop.